UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
LOS ANGELES, June 28, 2017 -- Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Roche Holding AG (“Roche Holding” or the “Company”) (Other OTC:RHHBY) for possible violations of federal securities laws from March 2, 2017 through June 5, 2017, inclusive (the “Class Period”). Investors who purchased or otherwise acquired Roche Holding shares during the Class Period should contact the firm prior to the August 7, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, throughout the Class Period, Roche Holding issued materially false and misleading statements and/or failed to disclose that the combination of the Company’s breast cancer drug, Perjeta, and its older treatment, Herceptin, is only marginally more effective than Herceptin alone in preventing breast cancer; and that as a result, Roche Holding’s statements about its business, operations and prospects were materially false and misleading and/or lacked a reasonable bases at all relevant times. When this news became public, Roche Holding’s stock price dropped materially, causing investors harm according to the Complaint.
Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
